We work with compassion and commitment in making a difference in the lives of patients
Get In Touch
We partner with companies globally to introduce innovations in Asia in the areas of speciality treatments
Get In Touch
We continuously look for opportunities for successful collaborations to bridge therapies to patients
Get In Touch

AxxessBio is a distributor of pharmaceutical products incorporated in Singapore in 2011 by professional executives in the biotech and pharmaceutical industries.

AxxessBio partners with companies globally to introduce innovations in Asia in the areas of speciality treatments.

We actively look for therapeutic solutions particularly in the areas of Hematology, Oncology, Neonatology, Rare Diseases, Metabolic Diseases and Other Speciality Therapeutics. Read more.

【Special Offer】Rolex Submariner 116610LN Automatic Men’s WatchReplica Watches Store with Diamonds and Blue Plate .


AxxessBio creates a fully integrated solution to ensure AccessiBility of your life-changing therapies

AxxessBio Partners

Our Market Access Model

At AxxessBio, we bring the right treatments at the right time

By partnering with us, we develop a market access program to ensure your innovative therapies are made accessible to patients

Early access to Patients

We bring your innovative therapies to patients on an expedited basis prior to registration 

Timely access to Market

We ensure timely access to market through an integrated solution

Sustained access to Funding

We support patients to obtain funding for treatment 

Latest News and Releases

AxxessBio partners with Gennisium in the area of Neonatology

October 2020, Gennisium Pharma grants exclusive distribution rights to AxxessBio in Asia for Gencebok®.   Gencebok® (caffeine citrate) is indicated for the treatment of primary apnea of premature newborns. Caffeine citrate is the standard treatment for this conditon.   Apnea in preterm infants is common in babies born at less

Read More »

AxxessBio and Dipharma provide solutions for metabolic diseases

October 2020, an exclusive agreement has been signed between AxxessBio and Dipharma  SA for Sapropterin and Miglustat in selected countries in Asia. Sapropterin and Miglustat are medicines for rare metabolic diseases. Sapropterin is indicated for Phenylketonuria and BH4 Deficiency. Miglustat is indicated for Type 1 Gaucher Disease and Niemann-Pick C Disease.  

Read More »

Interested in Partnering Up?

At AxxessBio, we are continuously looking for partnerships to bring new innovative therapies for patients all around Asia